MENLO PARK, Calif.--(BUSINESS WIRE)--Oct. 1, 2020--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the company’s participation at IO Combinations 360˚ which will be held online, October 1-2, 2020.
The presentation, titled “Comprehensive immunogenomics to enable composite biomarkers for immunotherapy response using a sample sparing approach,” will describe the Personalis universal cancer immunogenomics platform, ImmunoID NeXT™. Travis Yates, PhD, will present for Personalis.
Dr. Yates will discuss the benefits of this unique, innovative design for immuno-oncology translational research, including mastering challenging samples, utilizing optimized algorithms, and obtaining accurate genomic data for identifying novel predictors of response. He will review a case study from a cohort of metastatic melanoma patients treated with an immune checkpoint blockade and will highlight the analytical capabilities provided by this immunogenomic profiling solution for understanding mechanisms of tumor evasion and creating composite biomarkers. Additionally, he will introduce NeXT Liquid Biopsy™, an exome-wide liquid biopsy approach combined with ImmunoID NeXT, to further explore critical areas of tumor biology.
About Personalis, Inc.
Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis’ services for the VA MVP, the company’s business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including the company’s most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005978/en/
Media Contact for Personalis:
Source: Personalis, Inc.